The role of adherence to inhaled corticosteroids in the relationship between blood eosinophilia and asthma control

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/26263
• EU PAS number:
  EUPAS11512
• Study ID:
  26263
• Official title and acronym:
  The role of adherence to inhaled corticosteroids in the relationship between blood eosinophilia and asthma control
• DARWIN EU® study:
  No
• Study countries:
  United Kingdom
• Study description:
  Patients with asthma and >0.4x109 blood eosinophils/L are characterized by increased severe exacerbation rates, reduced odds of achieving asthma control and being at higher steps of the GINA guidelines (step 3-4), compared to patients with asthma and lower eosinophil counts (<0.4x109/L).Alternative therapies that target raised eosinophil counts are being introduced to the market but there is some concern that these treatments will only work for patients with poor adherence to their asthma therapy.A recent RiRL study found that within the UK, a high proportion of patients at higher GINA steps appear to be adherent to therapy but remain uncontrolled in terms of exacerbations and symptoms. Therefore, there is a need to clarify whether there exists a population of patients with asthma who have persistent elevated blood eosinophil counts, persistent exacerbations and who are adherent to ICS.
• Study status:
  Finalised

Research institutions and networks

Institutions

Observational & Pragmatic Research Institute Pte (OPRI)

United Kingdom

Study timelines

Date when funding contract was signed

Actual: 01/03/2015

Study start date

Actual: 30/03/2015

Date of final study report

Planned: 30/12/2015

Actual: 30/12/2015

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Teva

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable